Senate committee opens drug pricing investigation
Leaders of the Senate Special Committee on Aging today announced a bipartisan investigation into pharmaceutical drug pricing. Committee Chairman Susan Collins (R-ME) and Ranking Member Claire McCaskill (D-MO) have asked four pharmaceutical companies to provide information in relation to recent price increases in off-patent drugs: Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin Inc and Rodelis Therapeutics. The committee has tentatively scheduled an initial hearing on the issue for Dec. 9.
Related News Articles
Headline
The Senate Committee on Health, Education, Labor and Pensions today held the second in a series of hearings on the cost of prescription drugs. “We…
Headline
The Senate Finance Committee today held a hearing on issues impacting health care costs and coverage. Witnesses included former Centers for Medicare &…
Headline
President Trump Friday signed into law the FDA Reauthorization Act (H.R. 2430). The bill reauthorizes and amends four FDA user fee programs under which…
Headline
The average monthly premium for a basic Medicare Part D prescription drug plan in 2018 is estimated to be $33.50 per month – or approximately $1.20 less…
Headline
The Senate yesterday voted 94-1 to approve the FDA Reauthorization Act (H.R. 2430), sending the legislation to the president for his signature. The bill…
Headline
Senate Democratic Leader Charles Schumer and House Democratic Leader Nancy Pelosi today unveiled an economic plan focused on improving wages, lowering costs…